Iris Burkholder

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

Ralf‐Dieter Hofheinz, Frederik Wenz, Stefan Post et al. · The Lancet Oncology · 2012 · 507 citations

Medicine, Oncology, Chemotherapy +12

“ToxRTool”, a new tool to assess the reliability of toxicological data

Klaus Schneider, Markus Schwarz, Iris Burkholder et al. · Toxicology Letters · 2009 · 427 citations

Pharmacy, Toxicology, Regulatory Toxicology +9

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

Simone Steinbild, K. Mross, Annette Frost et al. · British Journal of Cancer · 2007 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group

Eckart Laack, N. Dickgreber, Thomas Müller et al. · Journal of Clinical Oncology · 2004 · 90 citations · Full text

Medicine, Oncology, Pharmacology +11

Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial

Stephanie E. Combs, Iris Burkholder, Lutz Edler et al. · BMC Cancer · 2010 · 88 citations · Full text

Medicine, Oncology, Radiation Oncology +17